Systematic Reviews
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. May 6, 2016; 7(2): 294-305
Published online May 6, 2016. doi: 10.4292/wjgpt.v7.i2.294
Adverse events of sacral neuromodulation for fecal incontinence reported to the federal drug administration
Klaus Bielefeldt
Klaus Bielefeldt, Division of Gastroenterology, University of Pittsburgh Medical Center, Pittsburgh, PA 15217, United States
Author contributions: Bielefeldt K contributed to the manuscript.
Conflict-of-interest statement: The author has no conflict of interest.
Data sharing statement: Technical appendix and dataset are available from the corresponding author at bielefeldtk@upmc.edu.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Klaus Bielefeldt, MD, PhD, Division of Gastroenterology, University of Pittsburgh Medical Center, 200 Lothrop St. Pittsburgh, PA 15217, United States. bielefeldtk@upmc.edu
Telephone: +1-412-8647087 Fax: +1-412-6489378
Received: December 19, 2015
Peer-review started: December 22, 2015
First decision: February 22, 2016
Revised: February 23, 2016
Accepted: March 14, 2016
Published online: May 6, 2016
Abstract

AIM: To investigate the nature and severity of AE related to sacral neurostimulation (SNS).

METHODS: Based on Pubmed and Embase searches, we identified published trials and case series of SNS for fecal incontinence (FI) and extracted data on adverse events, requiring an active intervention. Those problems were operationally defined as infection, device removal explant or need for lead and/or generator replacement. In addition, we analyzed the Manufacturer and User Device Experience registry of the Federal Drug Administration for the months of August - October of 2015. Events were included if the report specifically mentioned gastrointestinal (GI), bowel and FI as indication and if the narrative did not focus on bladder symptoms. The classification, reporter, the date of the recorded complaint, time between initial implant and report, the type of AE, steps taken and outcome were extracted from the report. In cases of device removal or replacement, we looked for confirmatory comments by healthcare providers or the manufacturer.

RESULTS: Published studies reported adverse events and reoperation rates for 1954 patients, followed for 27 (1-117) mo. Reoperation rates were 18.6% (14.2-23.9) with device explants accounting for 10.0% (7.8-12.7) of secondary surgeries; rates of device replacement or explant or pocket site and electrode revisions increased with longer follow up. During the period examined, the FDA received 1684 reports of AE related to SNS with FI or GI listed as indication. A total of 652 reports met the inclusion criteria, with 52.7% specifically listing FI. Lack or loss of benefit (48.9%), pain or dysesthesia (27.8%) and complication at the generator implantation site (8.7%) were most commonly listed. Complaints led to secondary surgeries in 29.7% of the AE. Reoperations were performed to explant (38.2%) or replace (46.5%) the device or a lead, or revise the generator pocket (14.6%). Conservative management changes mostly involved changes in stimulation parameters (44.5%), which successfully addressed concerns in 35.2% of cases that included information about treatment results.

CONCLUSION: With reoperation rates around 20%, physicians need to fully disclose the high likelihood of complications and secondary interventions and exhaust non-invasive treatments, including transcutaneous stimulation paradigms.

Keywords: Sacral nerve stimulation, Implanted medical devices, Treatment complications, Defecation disorders, Device registry

Core tip: Sacral neuromodulation can improve fecal incontinence refractory to other treatments. However, adverse events are very common and often require additional operations. Many of the reported patient concerns surface early after stimulator implantation, respond to changes in stimulation parameters and may thus be considered a part of the routine maintenance of this treatment modality. Nonetheless, rates of surgical re-interventions are high and increase over time. Physicians counseling patients about this treatment for fecal incontinence should emphasize the likely need for such secondary surgeries and consider emerging non-invasive treatment options. In addition, prospective studies should compare less invasive paradigms, such as transcutaneous stimulation, with permanently implanted devices to more clearly define their differential impact.